Vident Advisory LLC Invests $95,000 in COMPASS Pathways PLC Sponsored ADR $CMPS

Vident Advisory LLC bought a new position in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 33,162 shares of the company’s stock, valued at approximately $95,000.

A number of other institutional investors also recently modified their holdings of CMPS. Cerity Partners LLC purchased a new stake in shares of COMPASS Pathways during the first quarter worth about $29,000. GAMMA Investing LLC boosted its holdings in shares of COMPASS Pathways by 93.6% during the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock worth $30,000 after purchasing an additional 5,003 shares during the period. Ethos Financial Group LLC purchased a new stake in shares of COMPASS Pathways during the first quarter worth about $35,000. Flagship Harbor Advisors LLC boosted its holdings in shares of COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company’s stock worth $41,000 after purchasing an additional 3,134 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of COMPASS Pathways during the first quarter worth about $41,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CMPS has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $12.00 target price on shares of COMPASS Pathways in a report on Tuesday, May 27th. Canaccord Genuity Group restated a “buy” rating and issued a $15.00 price objective on shares of COMPASS Pathways in a report on Friday, August 1st. HC Wainwright lowered their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, August 4th. Finally, Evercore ISI restated an “in-line” rating and issued a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, COMPASS Pathways currently has an average rating of “Moderate Buy” and a consensus price target of $16.29.

COMPASS Pathways Price Performance

Shares of NASDAQ CMPS opened at $5.05 on Thursday. COMPASS Pathways PLC Sponsored ADR has a fifty-two week low of $2.25 and a fifty-two week high of $7.53. The company has a 50 day simple moving average of $4.29 and a two-hundred day simple moving average of $3.88. The company has a market capitalization of $484.50 million, a price-to-earnings ratio of -2.74 and a beta of 2.17. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.82 and a current ratio of 8.82.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Analysts expect that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.